What are the detailed regimens for low‑dose therapy and standard sequential therapy in drug‑susceptible pulmonary tuberculosis?

TB Treatment: Low-Dose and Sequential Therapy

The terms "low-dose therapy" and "sequential therapy" as distinct treatment strategies are not recognized or recommended in current tuberculosis treatment guidelines. Modern TB treatment does not utilize these approaches as defined therapeutic regimens 1, 2.

What Current Guidelines Actually Recommend

For Drug-Susceptible TB

Standard dosing (not "low-dose") with sequential phases is the established approach:

• Intensive Phase (2 months): Isoniazid (H), Rifampin (R), Pyrazinamide (Z), and Ethambutol (E) given daily
• Continuation Phase (4 months): Isoniazid and Rifampin given daily 1

This 2HRZE/4HR regimen represents the traditional 6-month treatment, where drugs are given in full therapeutic doses throughout, not reduced doses.

Newer Shortened Regimens (2025 Update)

For adults with drug-susceptible pulmonary TB:

• A 4-month regimen using rifapentine, isoniazid, moxifloxacin, and pyrazinamide (HPMZ) is now recommended as an alternative to the 6-month regimen 2
• This is a shorter duration regimen, not a "low-dose" regimen

For children (3 months to 16 years) with nonsevere TB:

• A 4-month regimen of 2HRZ(E)/2HR is strongly recommended over the traditional 6-month regimen 2

Why "Low-Dose" is Not Used

Full therapeutic dosing is critical throughout TB treatment to:

• Prevent emergence of drug resistance
• Ensure adequate bacterial killing
• Achieve cure and prevent relapse

Reducing drug doses below therapeutic levels would compromise treatment efficacy and promote resistance development 1, 3.

Understanding "Sequential" in TB Context

If by "sequential therapy" you mean the two-phase treatment structure, this is standard practice:

1. Intensive Phase: Uses 3-4 drugs to rapidly reduce bacterial burden and prevent resistance
2. Continuation Phase: Uses 2 drugs to eliminate remaining dormant bacilli 1, 4

This is not "sequential" in the sense of switching drugs due to failure, but rather a planned reduction in drug number after initial bacterial clearance.

Common Pitfalls to Avoid

• Never reduce drug doses below recommended therapeutic levels in an attempt to minimize toxicity—this promotes resistance
• Do not confuse shorter duration regimens (4 months vs 6 months) with "low-dose" therapy
• Sequential drug substitution only occurs when managing adverse drug reactions, not as a planned treatment strategy 1

When Drug Modifications Are Appropriate

Drug changes occur only in specific circumstances:

• Treatment-limiting adverse drug reactions: Replace the offending drug with an alternative from a different class 1
• Drug-drug interactions: Adjust regimen based on specific interactions
• Drug resistance detected: Switch to appropriate drug-resistant TB regimen 5

If you encountered these terms in a specific clinical context or regional protocol, clarification of their intended meaning would be necessary, as they do not align with international TB treatment standards.